Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Resonance HealthASX:RHT +7.69% EV-to-EBITDA is 17.40 as of Jul. 28, 2026. The stock has 8 warning signs investors should review. Among 509 Healthcare Providers & Services companies, Resonance Health ranks worse than 72.1% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Resonance Health's enterprise value is A$26.17 Mil.
Resonance Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$1.50 Mil. Therefore, Resonance Health's EV-to-EBITDA for today is 17.40.
The historical rank and industry rank for Resonance Health's EV-to-EBITDA or its related term are showing as below:
ASX:RHT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -643.76 Med: -19.7 Max: 134.97
Current: 17.4
During the past 13 years, the highest EV-to-EBITDA of Resonance Health was 134.97. The lowest was -643.76. And the median was -19.70.
ASX:RHT's EV-to-EBITDA is ranked worse than 72.1% of 509
companies
in the Healthcare Providers & Services industry
Industry Median: 11.03
vs ASX:RHT: 17.40
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Resonance Health (ASX:RHT) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Resonance Health's PE Ratio (TTM) for today is calculated as:
Resonance Health's share price for today is A$0.056.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Resonance Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.001.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Resonance Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RHT vs VEEV, BTSG, HQY: EV-to-EBITDA Comparison
For the Health Information Services subindustry, Resonance Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Health EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Resonance Health's EV-to-EBITDA falls into.
Resonance Health's current Enterprise Value is A$26.17 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Resonance Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$1.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Resonance Health (ASX:RHT) has a EV-to-EBITDA of 17.40 as of Jul. 28, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Resonance Health. According to the industry distribution chart, Resonance Health ranks #367 out of 509 companies in the Healthcare Providers & Services industry, placing it in the top 72.1%.
Is Resonance Health's EV-to-EBITDA too high?
Resonance Health's current EV-to-EBITDA is 17.40. The Healthcare Providers & Services industry median EV-to-EBITDA is 11.03. Resonance Health's value of 17.40 is 57.8% above this industry median. Based on the distribution chart, Resonance Health ranks #367 out of 509 companies in the Healthcare Providers & Services industry, which is below the industry midpoint.
How does Resonance Health's EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Resonance Health ranks #367 out of 509 companies for EV-to-EBITDA. This places Resonance Health in the lower half of its industry. The industry median EV-to-EBITDA is 11.03. Resonance Health's value of 17.40 is 57.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.03, based on 509 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Resonance Health's current EV-to-EBITDA of 17.40 is 57.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Resonance Health. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Health's current EV-to-EBITDA is 17.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.12, compared to a current price of A$0.06 — trading 53.3% below its estimated fair value. The current EV-to-EBITDA is 17.40 and 57.8% above the Healthcare Providers & Services industry median of 11.03. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current EV-to-EBITDA is 17.40 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RHT has been successfully added to your 
